NASDAQ:NMRD Nemaura Medical (NMRD) Stock Price, News & Analysis → The only AI company to buy (From Porter & Company) (Ad) Free NMRD Stock Alerts $0.05 -0.01 (-18.15%) (As of 05/29/2024 ET) Add Compare Share Share Today's Range$0.05▼$0.0650-Day Range$0.03▼$0.0952-Week Range$0.03▼$1.25Volume186,883 shsAverage Volume63,891 shsMarket Capitalization$1.82 millionP/E RatioN/ADividend YieldN/APrice Target$2.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestSustainabilityTrends Get Nemaura Medical alerts: Email Address Nemaura Medical MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside5,443.2% Upside$2.50 Price TargetShort InterestN/ADividend StrengthN/ASustainability-0.97Upright™ Environmental ScoreNews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.49 out of 5 stars 3.5 Analyst's Opinion Consensus RatingNemaura Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageNemaura Medical has received no research coverage in the past 90 days.Read more about Nemaura Medical's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for NMRD. Previous Next 0.0 Dividend Strength Dividend YieldNemaura Medical does not currently pay a dividend.Dividend GrowthNemaura Medical does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreNemaura Medical has received a 69.97% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Continuous glucose monitoring systems", "Continuous substance abuse monitoring systems", and "Continuous alcohol monitoring systems" products. See details.Environmental SustainabilityThe Environmental Impact score for Nemaura Medical is -0.97. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Nemaura Medical this week, compared to 0 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nemaura Medical insiders have not sold or bought any company stock.Percentage Held by Insiders41.60% of the stock of Nemaura Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 4.41% of the stock of Nemaura Medical is held by institutions.Read more about Nemaura Medical's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Nemaura Medical is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nemaura Medical is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyThe only AI company to buyThe AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. About Nemaura Medical Stock (NASDAQ:NMRD)Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.Read More NMRD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NMRD Stock News HeadlinesMay 26, 2024 | investing.comNemaura Medical Inc (NMRD)May 24, 2024 | seekingalpha.comNXNN Nexeon Medsystems IncFebruary 23, 2024 | benzinga.comNemaura Medical Stock (OTC:NMRD) Earnings Dates and Earning CallsJanuary 22, 2024 | finance.yahoo.comMaxim Group LLC to Host the 2024 Healthcare IT Virtual Conference on Wednesday, January 24th & Thursday, January 25th at 9:00 A.M. ETJanuary 3, 2024 | finanznachrichten.deNemaura Medical, Inc: Important Update on Listing Status and Strategic DirectionJanuary 3, 2024 | finance.yahoo.comImportant Update on Listing Status and Strategic DirectionDecember 20, 2023 | markets.businessinsider.comBuy Rating Affirmed for Nemaura Medical on sugarBEAT Prospects and Market ExpansionDecember 13, 2023 | finanznachrichten.deNemaura Medical, Inc: Nemaura Medical Inc. Receives Positive Nasdaq Listing DecisionDecember 13, 2023 | finance.yahoo.comNemaura Medical Inc. Receives Positive Nasdaq Listing DecisionNovember 27, 2023 | msn.comNemaura Medical (NMRD) Price Target Increased by 54.55% to 8.67November 21, 2023 | finance.yahoo.comNemaura Medical Inc. Secures $10 Million Non-Dilutive Credit Facility to Fuel Strategic GrowthNovember 17, 2023 | msn.comNemaura (NMRD) to Expand in UK With Metabolic Health ProgramNovember 16, 2023 | finance.yahoo.comNemaura Medical First Half 2024 Earnings: US$0.13 loss per share (vs US$0.33 loss in 1H 2023)November 15, 2023 | finanznachrichten.deNemaura Medical, Inc: Nemaura Medical Reports Fiscal Second Quarter 2024 Results and Provides Business UpdateNovember 14, 2023 | seekingalpha.comAcutus Medical Non-GAAP EPS of -$0.52, revenue of $5.2MNovember 14, 2023 | finanznachrichten.deNemaura Medical, Inc: Nemaura Launches Direct to Consumer Offering of Metabolic Health Program in Combination with GLP-1 Weight Loss DrugsNovember 14, 2023 | finance.yahoo.comNemaura Launches Direct to Consumer Offering of Metabolic Health Program in Combination with GLP-1 Weight Loss DrugsNovember 13, 2023 | finance.yahoo.comNemaura Medical Reports Fiscal Second Quarter 2024 Results and Provides Business UpdateOctober 18, 2023 | msn.comSeaStar Medical gets FDA breakthrough status for cytokine storm deviceSeptember 26, 2023 | finance.yahoo.comNemaura Medical Announces Appointment of Mr Nikolai Rozanov as Strategic Adviser in Artificial Intelligence, to Assist in Development of its AI Health Coach, and Strengthen Outcomes in its CGM Based Metabolic and Type 2 Diabetes Programs.September 18, 2023 | finance.yahoo.comNemaura Medical to Present at the Maxim Group Emerging Growth in A.I. ConferenceSeptember 16, 2023 | seekingalpha.comNemaura Medical says compliance regain with Nasdaq rules not expectedSeptember 14, 2023 | finanznachrichten.deNemaura Medical, Inc: Nemaura Medical Provides Update on Nasdaq Compliance Status and ProcessSeptember 14, 2023 | finance.yahoo.comNemaura Medical Provides Update on Nasdaq Compliance Status and ProcessSeptember 14, 2023 | benzinga.comTop Penny Stock Gainers Momentum Watchlist (ORHB, GSAC, NMRD, SASI)See More Headlines Receive NMRD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nemaura Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/12/2024Today5/30/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:NMRD CUSIPN/A CIK1602078 Webnemauramedical.com Phone(646) 416-8000FaxN/AEmployees36Year FoundedN/APrice Target and Rating Average Stock Price Target$2.50 High Stock Price Target$2.50 Low Stock Price Target$2.50 Potential Upside/Downside+5,443.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,140,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-142.69% Debt Debt-to-Equity RatioN/A Current Ratio0.19 Quick Ratio0.03 Sales & Book Value Annual Sales$80,000.00 Price / Sales22.75 Cash FlowN/A Price / Cash FlowN/A Book Value($0.41) per share Price / Book-0.11Miscellaneous Outstanding Shares40,350,000Free Float23,566,000Market Cap$1.82 million OptionableOptionable Beta0.04 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Dewan Fazlul Hoque Chowdhury Ph.D. (Age 51)Chairman, Interim CFO, CEO, President and Principal Financial & Accounting Officer Comp: $338.58kDr. Arash Ghadar (Age 47)Chief Operating Officer Mr. Jay L. WarnerHead of U.S. Commercial OperationsMr. Thomas Bendix MortensenHead of E.U. Commercial Operations & MarketingMs. Samantha SandersGlobal Head of Digital ProgramsKey CompetitorsVenus ConceptNASDAQ:VEROSharps TechnologyNASDAQ:STSSNeuroMetrixNASDAQ:NUROIntelligent Bio SolutionsNASDAQ:INBSVivos TherapeuticsNASDAQ:VVOSView All CompetitorsInsidersArash Ghadar-GhadrBought 100,000 shares on 1/5/2024Total: $14,000.00 ($0.14/share)View All Insider Transactions NMRD Stock Analysis - Frequently Asked Questions Should I buy or sell Nemaura Medical stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nemaura Medical in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" NMRD shares. View NMRD analyst ratings or view top-rated stocks. What is Nemaura Medical's stock price target for 2024? 1 Wall Street analysts have issued twelve-month price objectives for Nemaura Medical's shares. Their NMRD share price targets range from $2.50 to $2.50. On average, they expect the company's stock price to reach $2.50 in the next year. This suggests a possible upside of 5,443.2% from the stock's current price. View analysts price targets for NMRD or view top-rated stocks among Wall Street analysts. How have NMRD shares performed in 2024? Nemaura Medical's stock was trading at $0.2190 at the beginning of 2024. Since then, NMRD stock has decreased by 79.4% and is now trading at $0.0451. View the best growth stocks for 2024 here. How were Nemaura Medical's earnings last quarter? Nemaura Medical Inc. (NASDAQ:NMRD) issued its earnings results on Monday, February, 12th. The company reported ($0.12) earnings per share (EPS) for the quarter. How do I buy shares of Nemaura Medical? Shares of NMRD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NMRD) was last updated on 5/30/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceWrite this ticker symbol down…StocksToTradeThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarBiden Nomination CANCELED?The Freeport SocietyBUY ALERT: Tiny tech play partners with US governmentStansberry ResearchGold Set to EXPLODE!Gold Safe Exchange[Urgent!] Generational Wealth GameplanCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nemaura Medical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.